Cape Investment Advisory, Inc. Recursion Pharmaceuticals, Inc. Transaction History
Cape Investment Advisory, Inc.
- $274 Billion
- Q2 2025
A detailed history of Cape Investment Advisory, Inc. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Cape Investment Advisory, Inc. holds 350 shares of RXRX stock, worth $1,931. This represents 0.0% of its overall portfolio holdings.
Number of Shares
350
Previous 350
-0.0%
Holding current value
$1,931
Previous $1.85 Million
4.37%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding RXRX
# of Institutions
367Shares Held
288MCall Options Held
7.76MPut Options Held
6.19M-
Vanguard Group Inc Valley Forge, PA36.1MShares$199 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl33MShares$182 Million1.38% of portfolio
-
Baillie Gifford & CO24.2MShares$133 Million0.1% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$95.6 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$81 Million0.31% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $996M
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...